Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/autre/cellular-therapies-for-retinal-disease/descriptif_3838047
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=3838047

0 article 

 Frais de port 0,01€*

Exclusivité web : à partir de 35 euros d’achat, frais de port à 1 centime pour les expéditions vers la France métropolitaine, la Suisse et l’UE avec Colissimo ou GLS

Cellular Therapies for Retinal Disease, Softcover reprint of the original 1st ed. 2017 A Strategic Approach

Langue : Anglais
Couverture de l’ouvrage Cellular Therapies for Retinal Disease
This book familiarizes the reader with the current landscape of cell-based therapies for the treatment of retinal disease, including diseases that affect the choriocapillaris, retinal pigment epithelium, photoreceptors, and retinal ganglion cells. Instead of utilizing a disease-centric approach to the topic, this book?edited by two world-renowned stem cell scientists?focuses on strategies for developing and transplanting the cells. This includes the creation of replacement cells, cell-based neuroprotection, and in vitro disease modeling and testing. The final chapters briefly review parallel approaches that do not directly utilize cellular transplantation.

The use of cellular transplantation to treat retinal disease has recently become a viable and exciting therapeutic approach. The visibility of the retina and its laminar cellular architecture render it an ideal organ for the development of surgically delivered cellular therapies. Having an in-depth understanding ofthe current state of cell therapy for the eye is an essential first step toward utilizing similar approaches in other organs. Ophthalmologists, translational clinician-scientists, stem cell scientists, and researchers interested in eye disease will find Cellular Therapies for Retinal Disease: A Strategic Approach essential reading and it is also suitable for workshops or courses at the undergraduate or Ph.D. level.
Part I- Cell Replacement Therapy.- 1. Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cell Transplantation for Retinal Degeneration.- 2. Stem Cell-Derived RPE transplantation: the feasibility and advantages of delivery as monolayers.- 3. Induced Pluripotent Stem Cell-Derived Autologous Cell Therapy for Age-related Macular Degeneration.- 4. Scaffolds for Cell Transplantation.- 5. Surgical Approaches for Cell Transplantation in Cell Replacement Therapy.- 6. Cell Transplantation Therapy for Glaucoma. Part II - Cell-based Neuroprotection.- 7. Autologous Bone Marrow-Derived Cell Therapies for Retinal Disease.- 8. Subretinal Delivery of Cells Via the Suprachoroidal Space: The Janssen Trial. Part III – Disease Modeling using Induced Pluripotent Stem Cells.- 9. “Disease in a Dish” Modeling of Retinal Diseases.- 10. Retinal Organoids: An Emerging Technology for Retinal Disease Research and Therapy.

Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology, the Stein Eye Institute at UCLA, is a recognized expert in translational research with a successful track record including contributions to anti-vascular endothelial growth factor therapeutics, drug delivery systems, vitreoretinal diagnostic imaging instrumentation, novel therapeutic lasers and surgical devices including a novel microsurgical robotic system. Currently he is leading the first clinical trials of human embryonic stem cell derived RPE transplanted into patients with Age Related Macular Degeneration and Stargardt macular degeneration.  His research is widely published with over 100 peer-reviewed publications including the lead article on the first in human successful stem cell therapy in the Lancet. He has received numerous awards for scientific, clinical and humanitarian contributions including the American Academy of Ophthalmology’s Secretariat Award.

Aaron Nagiel, MD, PhD is a second-year vitreoretinal fellow at the Stein Eye Institute at UCLA.  After graduating from Harvard College, he received MD and PhD degrees at Cornell University and The Rockefeller University in New York City.  He completed ophthalmology residency training at Stein and is a recipient of the Heed Ophthalmic Foundation Fellowship and the Ronald G. Michels Foundation Fellowship.  He has contributed to several publications on retinal imaging and cell-based therapies for retinal disease.

Robert Lanza, M.D. is currently Head of Astellas Global Regenerative Medicine, and is Chief Scientific Officer of the Astellas Institute for Regenerative Medicine and Adjunct Professor at Wake Forest University School of Medicine. He has several hundred publications and inventions, and over 30 scientific books: among them, “Essentials of Stem Cell Biology” and “Principles of Tissue Engineering” which are recognized as the definitive references in the field. He is a former Fulbrig

Drs. Schwartz and Lanza are two of the best known names in stem cell research and Dr. Schwartz is known particularly for clinical trials for stem cell therapies for ophthalmologic diseases Focuses on strategies for developing and transplanting cells rather than taking a disease-centric approach Contains chapters that review parallel other approaches not involving cellular transplantation

Date de parution :

Ouvrage de 143 p.

21x27.9 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

147,69 €

Ajouter au panier

Date de parution :

Ouvrage de 143 p.

21x27.9 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

147,69 €

Ajouter au panier